CONFERENCE COVERAGE SERIES
European Federation of Neurological Societies
Stockholm, Sweden
11 September 2012
Bapineuzumab Phase 3: Target Engagement, But No Benefit
Bapineuzumab prevents accumulation of Aβ in the brain and lowers phospho-tau (p-tau) in cerebrospinal fluid (CSF), according to analysis...